Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -29.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $3M | — | — | — | — | — |
| Enterprise Value | $4M | $5M | — | — | — | — | — |
| P/E Ratio → | -0.08 | — | — | — | — | — | — |
| P/S Ratio | 0.50 | 0.87 | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.02 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.80 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 20.4% | 20.4% | 23.0% | — | — | — | — |
| Operating Margin | -631.0% | -631.0% | -331.2% | — | — | — | — |
| Net Profit Margin | -619.8% | -619.8% | -292.6% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -29.9% | -29.9% | -79.4% | 2.5% | -92.3% | — | -2004.4% |
| ROA | -20.8% | -20.8% | -53.1% | 2.2% | -8.8% | -0.6% | -7.4% |
| ROIC | -22.0% | -22.0% | -63.3% | -8.4% | -11.3% | -0.8% | — |
| ROCE | -24.5% | -24.5% | -77.5% | -10.6% | -79.3% | — | -2004.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | — | 0.02 | — | 252.53 |
| Debt / EBITDA | — | — | — | — | 0.01 | 1.71 | 1.64 |
| Net Debt / Equity | — | 0.02 | — | -0.00 | -0.01 | — | 199.79 |
| Net Debt / EBITDA | — | — | — | -0.02 | -0.01 | 1.69 | 1.30 |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -56.07 | -56.07 | -275.31 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | 0.16 | 0.07 | 0.01 | 0.75 | 0.01 | 0.19 |
| Quick Ratio | 0.15 | 0.15 | 0.07 | 0.01 | 0.57 | 0.01 | 0.19 |
| Cash Ratio | 0.10 | 0.10 | 0.01 | 0.01 | 0.48 | 0.01 | 0.19 |
| Asset Turnover | — | 0.02 | 1.53 | — | — | — | — |
| Inventory Turnover | 11.77 | 11.77 | — | — | — | — | — |
| Days Sales Outstanding | — | 75.25 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $4M | $4M | $8M | $9M | $8M | $8M |
Imminent liquidity depletion risk
According to recent market data, OSRH trades at a price-to-sales ratio of 0.50, which appears to reflect a market pricing the entity as a distressed asset rather than a growth-oriented biotechnology firm, especially given the -17.69% year-over-year revenue decline reported in recent financial filings.
The low P/S multiple suggests that investors are heavily discounting the company's future clinical prospects, likely due to the lack of a clear commercialization path. This valuation level implies that the market is essentially assigning little to no value to the underlying intellectual property, viewing the company primarily through the lens of its limited cash runway.
Based on reported figures, OSRH's ROIC has trended into negative territory, reaching -2.1% in 2026Q1, which indicates that the company is currently destroying value rather than compounding it as it attempts to transition its operational focus toward oncology and ophthalmology research.
The persistent negative returns on invested capital suggest that the capital deployed during the SPAC merger has not yet been converted into productive clinical assets. Without a significant breakthrough in its therapeutic pipeline, the company appears unable to generate returns that exceed its cost of capital, further complicating future fundraising efforts.
As reported in financial statements, OSRH's cash conversion cycle has shown extreme volatility, swinging from -2627 days in 2025Q4 to -148 days in 2026Q1, which suggests that the company is relying on aggressive and inconsistent timing of payables to manage its severely constrained liquidity position.
The erratic nature of these efficiency metrics indicates a lack of operational maturity and a reliance on sporadic cash management tactics. Investors should monitor whether these fluctuations are a result of intentional working capital optimization or a symptom of broader operational instability within the firm's administrative and research functions.
According to recent SEC filings, OSRH's current ratio has plummeted to 0.16 as of 2026Q1, reflecting a critical inability to cover short-term liabilities with existing cash reserves, which appears insufficient to sustain the company's high-burn operating model for more than a few quarters without external intervention.
This liquidity profile suggests that the company is in a precarious position where even minor operational delays could lead to a funding crisis. The reliance on such a thin cash buffer leaves the firm highly vulnerable to market volatility and may force management to pursue dilutive financing options to maintain basic operations.
Based on the company's current stage, the P/E ratio is a fundamentally misapplied metric, as it obscures the reality that OSRH is a pre-profit clinical-stage entity where earnings are non-existent and current losses are driven by necessary, albeit high, research and development expenditures.
Analysts should instead focus on cash burn rates and the remaining clinical runway, as traditional valuation multiples like P/E or EV/EBITDA fail to capture the binary nature of biotech success. Using earnings-based metrics for OSRH provides a distorted view of the company's health, as it ignores the potential value of the underlying IP that is not yet reflected in the income statement.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OSRH stock.
OSR Holdings, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
OSR Holdings, Inc.'s return on equity (ROE) is -29.9%. The historical average is -49.8%.
Based on historical data, OSR Holdings, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
OSR Holdings, Inc. has 20.4% gross margin and -631.0% operating margin.